OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 17:22 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction

NCT03127592 · Apsen Farmaceutica S.A. · PHASE3 · terminated · last registry update 2026-09-09 · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“recruitment difficulty”–Registry record, Apsen Farmaceutica S.A.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against CHRM3 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision